STOK — Stoke Therapeutics, Inc. stock price, charts and financials

Latest market price

32.24

-0.47-1.44%

Overview Short InterestFilings

STOKQT71Stoke Therapeutics, Inc.·NASDAQ

Overview Short InterestFilings

32.24-1.44%

Loading chart...

Signal & projected range

Insider open-market saleHistorical pattern — not a prediction

Recent priceDays this stock last showed the setupRange of past outcomes (±1σ)

Horizon

Unlock the projected rangeSee where this setup landed historically — with Premium.

Over the next 20 trading days, similar setups historically landed in a measured range of outcomes. Premium shows the median return, the typical range, and how often they were positive. This is the historical range of outcomes — not a prediction of this stock’s price.

Ranges describe how this exact setup resolved in the past — derived from thousands ofhistorical occurrences across QuoTrend’s coverage since 2006, survivorship-corrected to include companies that later delisted. The band is the typical spread (±1σ) of those outcomes, not a forecast; the central value is their average move. Fewer matching cases over longer horizons widen the band and lower its reliability. Backtested results are hypothetical, based on historical data, and do not represent actual trading. Past performance does not guarantee or predict future results. QuoTrend is an educational research tool, not investment advice. Markets involve risk, including loss of principal.

Screen all →

ABCL+36.08%$9.43 VRDN-2.67%$22.96 TSHA-1.45%$6.46 GHRS-1.72%$29.75 RAPP+1.96%$46.38 ZBIO-0.58%$32.24 MESO+4.23%$16.61 AUPH-2.33%$15.48

Snapshot

Index	-	P/E	-	EPS (ttm)	-2.83	Insider Own	21.89%	Shs Outstand	64.53M	Perf Week	13.34%

Market Cap	2.11B	Forward P/E	-	EPS next Y	-3.52	Insider Trans	-0.79%	Shs Float	48.45M	Perf Month	-0.37%

Enterprise Value	2.00B	PEG	-	EPS next Q	-	Inst Own	-	Short Float	32.39%	Perf Quarter	-0.24%

Income	-203.26M	P/S	76.51	EPS this Y	-27.89%	Inst Trans	-	Short Ratio	22.32	Perf Half Y	7.32%

Sales	27.59M	P/B	6.25	EPS next Y	2.64%	ROA	-52.77%	Short Interest	15.69M	Perf YTD	3.06%

Book/sh	-	P/C	-	EPS next 5Y	-	ROE	-59.36%	52W High	39.64 -18.67%	Perf Year	148.37%

Cash/sh	-	P/FCF	-	EPS past 3/5Y	-	ROIC	-62.74%	52W Low	12.68 154.35%	Perf 3Y	422.52%

Dividend Est.	-	EV/EBITDA	-	Sales past 3/5Y	148.43% -	Gross Margin	84.67%	Volatility	6.52% 5.65%	Perf 5Y	14.25%

Dividend TTM	-	EV/Sales	72.62	EPS Y/Y TTM	-70.30%	Oper. Margin	-809.69%	ATR (14)	1.64	Perf 10Y	-

Dividend Ex-Date	-	Quick Ratio	7.69	Sales Y/Y TTM	-	Profit Margin	-753.60%	RSI (14)	63.54	Recom	2.19

Dividend Gr. 3/5Y	-	Current Ratio	7.69	EPS Q/Q	-141.58%	SMA20	9.78%	Beta	1.20	Target Price	47.33

Payout	0.00%	Debt/Eq	0.01	Sales Q/Q	-96.23%	SMA50	7.50%	Rel Volume	1.09	Prev Close	32.71

Employees	170	LT Debt/Eq	0.01	Earnings	Nov 03	SMA200	3.58%	Avg Volume	792.70K	Price	32.24

IPO Date	Jun 19, 2019	Option/Short	Yes / Yes	EPS/Sales Surpr.	2.17% -3.92%	Net Debt/EBITDA	0.52	Volume	866,577	Change	-1.44%

Analyst Ratings

Date	Action	Analyst	Rating	Target
Aug-04-26	Reiterated	Canaccord Genuity	Buy	$36 → $58
Jul-13-26	Initiated	Goldman Sachs	Buy	$44
Feb-23-26	Initiated	Wolfe Research	Outperform	$40
Feb-05-26	Initiated	Guggenheim	Buy	$60
Jan-12-26	Reiterated	Wedbush	Outperform	$36
Jan-05-26	Reiterated	Loop Capital Markets		$35
Jan-05-26	Reiterated	Canaccord Genuity	Buy	$28 → $36
Dec-15-25	Reiterated	UBS	Neutral	$35 → $50
Dec-15-25	Reiterated	HC Wainwright & Co.	Buy	$35 → $50
Nov-05-25	Reiterated	Canaccord Genuity	Buy	$20 → $28

Latest News

Aug-05-26

Aug-05-2604:33AM

Dimensional Fund Advisors LP Buys 162,797 Shares of Stoke Therapeutics, Inc. $STOKdefenseworld.net

Aug-04-26

Aug-04-2610:07AM

Guggenheim Reiterates Buy on Stoke Therapeutics, Maintains $60 Price TargetBenzinga

09:28AM

These Analysts Revise Their Forecasts On Stoke Therapeutics After Q2 Resultsbenzinga.com

05:39AM

Stoke Therapeutics, Inc. (STOK) Q2 2026 Earnings Call Transcriptseekingalpha.com

Aug-03-26

Aug-03-2606:11PM

Stoke Therapeutics, Inc. (STOK) Reports Q2 Loss, Tops Revenue Estimateszacks.com

06:04PM

Stoke Therapeutics Q2 Earnings Call Highlightsmarketbeat.com

04:01PM

Stoke Therapeutics Announces Second Quarter 2026 Financial Results and Provides Business Updatesbusinesswire.com

Jul-27-26

Jul-27-2604:01PM

Stoke Therapeutics to Host Webcast and Conference Call to Discuss Second Quarter 2026 Business and Financial Updatesbusinesswire.com

Jul-19-26

Jul-19-2602:15AM

Stoke Therapeutics: Its Dravet Syndrome Lead Asset Enters The Last StretchSeekingAlpha

Jul-16-26

Jul-16-2604:01PM

Stoke Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)businesswire.com

Jul-13-26

Jul-13-2605:43AM

Goldman Sachs Initiates Coverage On Stoke Therapeutics with Buy Rating, Announces Price Target of $44Benzinga

Jun-30-26

Jun-30-2608:00AM

Stoke Therapeutics Announces Completion of Enrollment of 162 Patients Into the Phase 3 EMPEROR Study of Zorevunersen, an Investigational Medicine for the Treatment of Dravet Syndromebusinesswire.com

Company

Stoke Therapeutics, Inc. is an emerging biopharmaceutical company dedicated to developing innovative antisense oligonucleotide (ASO) therapies. Its primary focus is to target and address the fundamental causes of severe genetic disorders, particularly within the United States. The company employs its exclusive Targeted Augmentation of Nuclear Gene Output (TANGO) platform to engineer ASOs that precisely enhance protein expression. Stoke's most advanced candidate, STK-001, is currently progressing through Phase I/IIa clinical trials for Dravet syndrome, a severe and debilitating genetic epilepsy. Additionally, STK-002 is in the preclinical development stage for treating autosomal dominant optic atrophy. The company has also established a licensing and collaborative agreement with Acadia Pharmaceuticals Inc. to identify, develop, and market new RNA-based medicines for critical and rare genetic neurodevelopmental conditions impacting the central nervous system. Formerly known as ASOthera Pharmaceuticals, Inc., the company rebranded to Stoke Therapeutics, Inc. in May 2016. Founded in 2014, Stoke Therapeutics, Inc. maintains its headquarters in Bedford, Massachusetts.

Ownership

Per-holder 13F data hasn't been ingested for this ticker yet.

Financial Statements

DataTimeframe

Line Item (USD, M)	FY 2025 12/31/2025	FY 2024 12/31/2024	FY 2023 12/31/2023	FY 2022 12/31/2022	FY 2021 12/31/2021	FY 2020 12/31/2020	FY 2019 12/31/2019	FY 2018 12/31/2018	FY 2017 12/31/2017
Total Revenue	184	37	9	—	—	—	—	—	—
Cost of Goods Sold Incl. D&A	0	0	0	—	—	—	—	—	—
Gross Profit	184	37	9	—	—	—	—	—	—
Selling, General and Administrative Excl. Other	67	49	41	—	—	—	—	—	—
Research and Development	138	89	82	—	—	—	—	—	—
Other Operating Expense	0	0	1	—	—	—	—	—	—
Operating Income	-21	-101	-115	—	—	—	—	—	—
Interest Expense	0	0	0	—	—	—	—	—	—
Unusual Expense	—	—	—	—	—	—	—	—	—
Non-Operating Income (Expense)	14	12	10	—	—	—	—	—	—
Net Income Before Taxes	-7	-89	-105	—	—	—	—	—	—
Income Taxes	0	0	0	—	—	—	—	—	—
Consolidated Net Income	-7	-89	-105	—	—	—	—	—	—
Net Income From Continuing Operations	-7	-89	-105	—	—	—	—	—	—
Net Income	-7	-89	-105	—	—	—	—	—	—
EPS (Recurring)	-0.12	-1.65	-2.38	—	—	—	—	—	—
EPS (Basic, Before Extraordinaries)	-0.12	-1.65	-2.38	—	—	—	—	—	—
EPS (Diluted)	-0.12	-1.65	-2.38	—	—	—	—	—	—
EBITDA	-5	-87	-102	—	—	—	—	—	—
Other After Tax Adjustments	—	—	—	—	—	—	—	—	—
Stock Option Compensation Expense	—	—	—	—	—	—	—	—	—
Price To Earnings Ratio	—	—	—	—	—	—	—	—	—
Price To Sales Ratio	10.18	16.10	25.72	—	—	—	—	—	—
Gross Margin	100.00	100.00	100.00	—	—	—	—	—	—
Operating Margin	-11.41	-272.97	-1,277.78	—	—	—	—	—	—
Net Margin	-3.80	-240.54	-1,166.67	—	—	—	—	—	—
Shares Outstanding	59	54	44	—	—	—	—	—	—
Market Capitalization	1,873	596	231	—	—	—	—	—	—
Operating Lease Expense	—	—	—	—	—	—	—	—	—

Unlock full historical data

See years of past statements with Premium.

Insider Trading Volume

Insider Trading

Insider	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
Ticho Barry	CHIEF MEDICAL OFFICER	Aug 03 '26	Sale	29.04	7,176	208,385	20,422	Aug 05
Ticho Barry	CHIEF MEDICAL OFFICER	Jul 01 '26	Sale	32.66	7,228	236,068	27,598	Jul 06
Allan Jonathan	GENERAL COUNSEL & CORP SEC	Jun 16 '26	Sale	29.95	1,457	43,637	18,086	Jun 18
Ticho Barry	CHIEF MEDICAL OFFICER	Jun 01 '26	Sale	30.58	1,795	54,891	34,826	Jun 03
Ticho Barry	CHIEF MEDICAL OFFICER	May 01 '26	Sale	32.79	2,243	73,548	36,621	May 05
Ticho Barry	CHIEF MEDICAL OFFICER	Apr 01 '26	Sale	32.66	1,838	60,029	38,864	Apr 03
Allan Jonathan	GENERAL COUNSEL & CORP SEC	Mar 20 '26	Sale	33.69	9,293	313,038	19,543	Mar 24
Ticho Barry	CHIEF MEDICAL OFFICER	Mar 19 '26	Sale	29.99	1,461	43,815	40,702	Mar 19
Ticho Barry	CHIEF MEDICAL OFFICER	Mar 19 '26	Option Exercise	2.19	1,365	2,989	42,163	Mar 19
Leggett Thomas	Chief Financial Officer	Mar 18 '26	Sale	31.34	2,382	74,663	10,172	Mar 19
Hoitt Jason	Chief Patient Officer	Mar 18 '26	Sale	31.34	1,931	60,527	10,276	Mar 19
Allan Jonathan	GENERAL COUNSEL & CORP SEC	Mar 18 '26	Sale	31.34	4,628	145,062	28,836	Mar 19
Ticho Barry	CHIEF MEDICAL OFFICER	Mar 18 '26	Sale	31.34	6,686	209,569	40,798	Mar 19
Ticho Barry	CHIEF MEDICAL OFFICER	Mar 17 '26	Sale	33.01	6,164	203,451	47,484	Mar 19
Leggett Thomas	Chief Financial Officer	Mar 17 '26	Sale	33.01	2,196	72,482	12,554	Mar 19

open in yahoo·open in reuters·open in marketwatch·open in google·open in EDGAR

QuoTrend signals describe historical patterns and statistics — educational information, not investment advice or a recommendation to buy or sell. Past performance doesn’t guarantee future results. Every figure traces to QuoTrend data. Historical patterns — not a prediction or advice.